| Preferred IUPAC name
| Systematic IUPAC name
|3D model (Jmol)|| Interactive image|
|Molar mass||316.480 g/mol|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|(what is ?)|
JNJ-5207852 is a histamine antagonist selective for the H3 subtype. It has stimulant and nootropic effects in animal studies, and has been suggested as a possible treatment for memory defects associated with epilepsy. JNJ-5207852 itself did not progress to clinical development due to poor pharmacokinetic characteristics, but the related compound JNJ-17216498 is currently in Phase II clinical trials for the treatment of narcolepsy.
- Barbier AJ, Berridge C, Dugovic C, et al. (November 2004). "Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H3 antagonist". Br. J. Pharmacol. 143 (5): 649–61. doi:10.1038/sj.bjp.0705964. PMC 1575430. PMID 15466448.
- Jia F, Kato M, Dai H, Xu A, Okuda T, Sakurai E, Okamura N, Lovenberg TW, Barbier A, Carruthers NI, Iinuma K, Yanai K. Effects of histamine H(3) antagonists and donepezil on learning and mnemonic deficits induced by pentylenetetrazol kindling in weanling mice. Neuropharmacology. 2006 Mar;50(4):404-11. PMID 16310812
- Esbenshade TA, Browman KE, Bitner RS, Strakhova M, Cowart MD, Brioni JD (July 2008). "The histamine H3 receptor: an attractive target for the treatment of cognitive disorders". Br. J. Pharmacol. 154 (6): 1166–81. doi:10.1038/bjp.2008.147. PMC 2483387. PMID 18469850.